Med. praxi. 2022;19(1):58-61 | DOI: 10.36290/med.2022.008

Direct anticoagulants and general practitioner

doc. MUDr. Petr Dulíček, Ph.D., MUDr. Zuzana Thibaud, MUDr. Anna Mária Pejková, Mgr. Petr Sadílek
IV. interní hematologická klinika FN a LF v Hradci Králové

With regard to the aging population, there are more and more individuals on anticoagulation therapy for atrial fibrillation and venous thromboembolism. Number of patients on direct anticoagulants has been increased in the last 10 years and therefore also general practitioners get into the contact with them. General practitioners cannot prescribe these drugs yet, but it is important to be familiar with correct indications, dosage, monitoring and perioperative management.

Keywords: venous thromboembolism, direct anticoagulants, general practitioner.

Published: February 23, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P, Thibaud Z, Pejková AM, Sadílek P. Direct anticoagulants and general practitioner. Med. praxi. 2022;19(1):58-61. doi: 10.36290/med.2022.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Xarelto­‑epar­‑product­‑informationcs.pdf.
    2. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice­‑daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2018;100:453-461. Go to original source...
    3. Buller HR, Lensing AW, Prins MH, et al. A dose­‑ranging study evaluating once­‑daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein DVT Dose Ranging Study. Blood. 2008;112:2242-2247. Go to original source... Go to PubMed...
    4. Eliquis - Summary of Product Characteristics (2017) http://www.ema.europa.eu/docs/ en GB/document library/EPAR­‑Product Information/human/002148/WC500107728.pdf. Accessed 24 Aug 2017.
    5. Eliquis­‑epar­‑product­‑informationcs.pdf.
    6. Agnelli GI, Bulle HR, Cohen A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9):799-808. Go to original source... Go to PubMed...
    7. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. Go to original source... Go to PubMed...
    8. Lixiana­‑epar­‑product­‑informationcs.pdf.
    9. Pradaxa­‑epar­‑product­‑informationcs.pdf.
    10. Schulman S, Kearon C, Kalkat AK. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009;361:2342-2352. Go to original source... Go to PubMed...
    11. Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41 Suppl 1:33-39.Další literatura u autora a na www.medicinapropraxi.cz Go to original source... Go to PubMed...
    12. Patel JP, Byrne RA, Patel RK, et al. Progress in the monitoring of direct oral anticoagulant therapy. Br J Haematol. 2019;184(6):912-924. Go to original source... Go to PubMed...
    13. Tina MGu, Garcia DA, Sabath DE. Assessment of direct oral anticoagulant assay use in clinical practice. Journal of Thrombosis and Thrombolysis April. 2019;47:403-408. Go to original source... Go to PubMed...
    14. Kovacevic MP, Lupi KE, Wong A, et al. Evaluation of the Effect of Apixaban on INR in the Inpatient Population. J Cardiovasc Pharmacol Ther. 2019; 24(4):355-358. Go to original source... Go to PubMed...
    15. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015;39(3):288-294. Go to original source... Go to PubMed...
    16. Pollack CV, Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431-441. Go to original source... Go to PubMed...
    17. Connolly SJ, Milling TJ Jr, Eikelboom JW, el al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14): 1326-1335. doi: 10.1056/NEJMoa1814051. Go to original source... Go to PubMed...
    18. Marcos­‑Jubilar M, García Erce JA, Martínez­‑Calle N, et al. Safety and effectiveness of a prothrombin complex concentrate in approved and off­‑label indications.Transfus Med. 2019;29(4):268-274. Go to original source... Go to PubMed...
    19. Hoffman M, Goldstein JN, Levy JH. The impact of prothrombin complex concentrates when treating DOAC­‑associated bleeding: a review. Int J Emerg Med. 2018;11(1):55. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.